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In	antiphospholipid	syndrome	(APS),	antiphospholipid	antibodies	(aPL)	binding	to	β2	glycoprotein	I	(β2GPI)	
induce	endothelial	cell–leukocyte	adhesion	and	thrombus	formation	via	unknown	mechanisms.	Here	we	show	
that	in	mice	both	of	these	processes	are	caused	by	the	inhibition	of	eNOS.	In	studies	of	cultured	human,	
bovine,	and	mouse	endothelial	cells,	the	promotion	of	monocyte	adhesion	by	aPL	entailed	decreased	bioavail-
able	NO,	and	aPL	fully	antagonized	eNOS	activation	by	diverse	agonists.	Similarly,	NO-dependent,	acetyl-
choline-induced	increases	in	carotid	vascular	conductance	were	impaired	in	aPL-treated	mice.	The	inhibi-
tion	of	eNOS	was	caused	by	antibody	recognition	of	domain	I	of	β2GPI	and	β2GPI	dimerization,	and	it	was	
due	to	attenuated	eNOS	S1179	phosphorylation	mediated	by	protein	phosphatase	2A	(PP2A).	Furthermore,	
LDL	receptor	family	member	antagonism	with	receptor-associated	protein	(RAP)	prevented	aPL	inhibition	of	
eNOS	in	cell	culture,	and	ApoER2–/–	mice	were	protected	from	aPL	inhibition	of	eNOS	in	vivo.	Moreover,	both	
aPL-induced	increases	in	leukocyte–endothelial	cell	adhesion	and	thrombus	formation	were	absent	in	eNOS–/–	
and	in	ApoER2–/–	mice.	Thus,	aPL-induced	leukocyte–endothelial	cell	adhesion	and	thrombosis	are	caused	by	
eNOS	antagonism,	which	is	due	to	impaired	S1179	phosphorylation	mediated	by	β2GPI,	apoER2,	and	PP2A.	
Our	results	suggest	that	novel	therapies	for	APS	can	now	be	developed	targeting	these	mechanisms.
Introduction
The antiphospholipid syndrome (APS) is an autoimmune disorder 
characterized by the presence of circulating antiphospholipid anti-
bodies (aPL) and recurrent thrombosis (1). A link between APS and 
greater risk of atherosclerosis in peripheral and coronary arteries 
has also been established (2). aPL are directed not against phospho-
lipids, but rather against plasma proteins with affinity for anionic 
cell surface phospholipids, and a pathogenetically important major 
subset of aPL is directed against β2-glycoprotein I (β2GPI) (3–7). 
Binding of aPL to phospholipid-bound β2GPI causes its dimeriza-
tion, which further increases its affinity for negatively charged phos-
pholipids and cell surfaces (8). The endothelium is a primary target 
of aPL, and pathogenic autoantibody binding to β2GPI causes the 
upregulation of adhesion molecule expression and a proinflamma-
tory and prothrombotic endothelial cell phenotype (9). How aPL 
binding to β2GPI on the endothelial cell surface induces a trans-
membrane signal to modify endothelial cell behavior is unknown.
NO generated by the endothelial isoform of NOS (eNOS) is a key 
determinant of vascular health that regulates several physiological 
processes, including leukocyte adhesion, thrombosis, endothelial 
cell migration and proliferation, vascular permeability, and vas-
cular smooth muscle cell growth and migration (10). The eNOS 
enzyme, which generates NO upon the conversion of l-arginine to 
l-citrulline, is activated by numerous extracellular stimuli and is 
promoted primarily by increases in the phosphorylation of S1179 
(in bovine eNOS; S1177 in human eNOS) by PI3 kinase/Akt kinase 
and also by dephosphorylation of T497 (11–13). Whether aPL alter 
eNOS function is unknown.
To better understand the molecular basis of APS, we designed 
the present study to test the hypothesis that aPL-induced increases 
in leukocyte–endothelial cell adhesion and thrombus formation 
are caused by eNOS antagonism. In addition, we determined 
whether aPL-induced eNOS inhibition involves β2GPI, and if the 
process also requires an LDL receptor (LDLR) family member, par-
ticularly apoER2, which has the capacity to directly bind β2GPI 
(14, 15). Complementary experiments evaluating eNOS activation 
and leukocyte–endothelial cell adhesion were performed to link 
changes in enzyme activity with alterations in a key endothelial 
cell function that contributes to both the proinflammatory and 
the prothrombotic actions of aPL (16). Furthermore, the molecu-
lar underpinnings of eNOS antagonism by aPL were investigated 
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in studies of the mechanisms regulating eNOS phosphorylation 
and dephosphorylation.
Results
Increases in adhesion with aPL are due to decreased bioavailable NO. To 
begin to test the potential role of alterations in NO in the effects 
of aPL on endothelium, we performed studies of monocyte adhe-
sion to bovine aortic endothelial cells (BAECs). Representative 
high-power-field images are shown in Figure 1A. Compared with 
control conditions, treatment of BAECs with LPS, used as a posi-
tive control, predictably caused an increase in monocyte adhe-
sion. Whereas treatment of the endothelial cells with normal 
human IgG (NHIgG) obtained from healthy individuals had no 
effect, polyclonal aPL isolated from APS patients caused a marked 
increase in adhesion. The impact of aPL was fully reversed by 
addition of the NO donor S-nitroso-N-acetyl-dl-penicillamine 
(SNAP). Summary data from 3 independent experiments are 
shown in Figure 1B.
To further determine whether the aPL-induced increase in 
endothelial cell–monocyte interaction was due to the antagonism 
of NO production, we performed additional experiments with 
the eNOS agonist acetylcholine (Ach; Figure 1C). The increase 
in monocyte adhesion with LPS was predictably reversed by Ach. 
Whereas NHIgG had no effect on Ach attenuation of adhesion, 
polyclonal aPL completely prevented the blunting of adhesion by 
the eNOS agonist, and the impact of aPL on monocyte adhesion 
was fully reversed by the NO donor SNAP. Summary data from 
3 independent experiments are shown in Figure 1D. These results 
indicate that aPL-induced increases in monocyte adhesion to 
endothelium are due to decreased bioavailable NO.
aPL antagonize eNOS. To directly determine whether aPL inhibit 
eNOS activation, we pretreated BAECs with NHIgG or polyclonal 
aPL and evaluated eNOS stimulation by VEGF (Figure 2A). Where-
as VEGF caused a greater than a 2-fold increase in eNOS activity 
in NHIgG-treated cells, which is similar to the response in non-
treated cells (17), polyclonal aPL caused a marked attenuation in 
eNOS activation. Identical findings were obtained in studies per-
formed with human aortic endothelial cells (HAECs) (Figure 2B). 
To test the impact of aPL on eNOS activation by a different ago-
nist and to prepare for in vivo experiments in mice, we performed 
studies with Ach in MFLM-91U mouse endothelial cells (Figure 
2C). aPL blunted eNOS activation by Ach in the mouse endothelial 
cells. Thus, aPL attenuates eNOS activation by diverse agonists in 
bovine, human, and mouse endothelium.
Figure 1
aPL-mediated increases in monocyte 
adhesion are due to decreased bioavail-
able NO. (A) Monocyte adhesion to 
BAECs was evaluated under the following 
conditions: untreated control, LPS (100 
ng/ml), NHIgG (100 μg/ml), NHIgG + NO 
donor (SNAP, 20 μmol/l), aPL (100 μg/
ml), and aPL + NO donor. (B) Graph rep-
resenting summary data for A. (C) Mono-
cyte adhesion to BAECs was evaluated 
under the following conditions: untreated 
control, LPS, LPS + Ach (10 μmol/k), LPS 
+ Ach + NHIgG, LPS + Ach + aPL, and 
LPS + Ach + aPL + NO donor SNAP). (D) 
Graph representing summary data for C. 
In B and D, n = 4; *P < 0.05 versus control. 
Original magnification, ×40 (A and C).
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To determine whether aPL antagonism of eNOS is operative in 
vivo, we measured Ach-mediated changes in carotid vascular con-
ductance in C57BL/6 mice. Responses to Ach were sequentially 
evaluated at baseline, following NHIgG or polyclonal aPL admin-
istration, and following NOS antagonism with nitro-l-arginine 
methyl ester (L-NAME). Whereas the administration of NHIgG 
had no effect on Ach-mediated increases in vascular conductance 
(Figure 2D), aPL decreased the Ach response by 50% (Figure 2E). 
These findings demonstrate that the antagonism of eNOS by aPL 
observed in cultured endothelial cells also occurs in vivo.
eNOS antagonism and the resulting increase in adhesion with aPL are 
mediated by β2GPI. We first tested the role of β2GPI in eNOS antago-
nism by comparing the actions of polyclonal aPL with and without 
prior serum deprivation, which displaces β2GPI from the cell sur-
face (18, 19). In serum-exposed endothelial cells, aPL caused robust 
inhibition of eNOS activation by VEGF (Figure 3A). In contrast, 
after serum deprivation for 24 hours, which caused a loss of β2GPI 
bound to the cells (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI39828DS1), aPL 
did not inhibit eNOS activity. To directly assess the role of β2GPI, 
we examined the effect on eNOS activation of FC1, a mouse mono-
clonal aPL reactive with β2GPI (20). Whereas treatment with con-
trol mouse IgG did not attenuate eNOS activation by VEGF, FC1 
inhibited eNOS activation (Figure 3B). Since pathogenic aPL that 
recognize β2GPI are most often directed against domain I (21–27) 
and the epitope on β2GPI recognized by FC1 is unknown, experi-
ments were then performed to compare the effects of a monoclonal 
antibody to domain I (3F8) versus a monoclonal antibody against 
domain II of β2GPI (2aG4). Similar to polyclonal aPL, 3F8 caused 
complete inhibition of eNOS activation by VEGF; in contrast, 
2aG4 had no effect (Figure 3C). To delineate how β2GPI domain I– 
mediated eNOS antagonism impacts endothelial cell function, we 
performed monocyte adhesion experiments with BAECs treated 
with 3F8 (Figure 3D). Whereas the isotype-matched control IgG 
BBG had no effect on monocyte adhesion, 3F8 caused a marked 
increase in adhesion comparable to that observed with LPS, and 
treatment with the NO donor SNAP fully reversed the effect of 
3F8 as well as that of LPS. To further confirm the role of β2GPI 
in the increased adhesion induced by the impairment of NO pro-
duction, we performed additional studies with the eNOS agonist 
Ach (Figure 3E). Compared with control conditions, LPS caused 
an increase in monocyte adhesion, and this was reversed by Ach. 
Whereas NHIgG, BBG, and 2aG4 had no effect on Ach attenua-
tion of adhesion, both polyclonal aPL and 3F8 directed against 
domain I of β2GPI completely prevented the blunting of adhesion 
by the eNOS agonist. To test whether eNOS antagonism by aPL 
may be due to the dimerization of β2GPI, we examined the effect 
of purified β2GPI dimers on eNOS activation (Figure 3F). Whereas 
Figure 2
aPL antagonize eNOS. BAECs (A), HAECs (B), or MFLM-91U cells (C) were pretreated for 15 minutes with NHIgG or aPL (100 μg/ml), and 
eNOS activity was then measured under basal conditions or during stimulation with VEGF (100 ng/ml) or Ach (10 μmol/l) for 15 minutes. In A–C, 
n = 4; *P < 0.05 versus basal, †P < 0.05 versus NHIgG. (D and E) Male C57BL/6 mice were instrumented, and changes in carotid vascular con-
ductance, kHz/mmHg. in response to eNOS activation were compared in mice injected with NHIgG (D, 2 mg/mouse i.v.) and aPL (E, 2 mg/mouse 
i.v.). Dose responses to Ach were determined sequentially at baseline (filled circles), 60 minutes after administration of NHIgG or aPL (open 
circles), and 10 minutes after L-NAME administration (inverted triangles). In D and E, n = 6/group; *P < 0.05 versus baseline (ANOVA).
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monomeric β2GPI had no effect on VEGF-induced eNOS activa-
tion, dimerized β2GPI completely inhibited eNOS, paralleling the 
effect of 3F8. These cumulative findings indicate that β2GPI medi-
ates eNOS antagonism and the resulting increase in endothelial 
cell–monocyte adhesion caused by aPL, and that the underlying 
mechanism likely entails β2GPI dimerization.
Studies in mice suggest that there is an important role for 
complement in aPL-induced thrombosis and aPL-induced fetal 
loss (28–32). To determine whether complement participates in 
the proximal event of eNOS antagonism by aPL, we performed 
experiments evaluating eNOS activation in BAECs that were 
serum-exposed or maintained in heat-inactivated, complement-
free serum (Supplemental Figure 2A). aPL-mediated eNOS antag-
onism occurred in a similar manner under both conditions. The 
role of complement was further assessed in studies of endothelial 
cell–monocyte adhesion induced by the anti–β2GPI domain I anti-
body 3F8 (Supplemental Figure 2B). 3F8 caused similar increases 
in adhesion in BAECs that were serum-exposed or maintained in 
heat-inactivated, complement-free serum. Thus, complement is 
not required for the effects of aPL on eNOS or for the resulting 
increase in endothelial cell–monocyte adhesion.
The contribution of Fc receptors to the pathogenicity of aPL 
is controversial. There is evidence suggesting that aPL may exert 
thrombogenic effects via the crosslinking of activating Fc recep-
tors (FcγRIIA) and that polymorphisms in Fc receptor are a clini-
cal predictor of relative thrombosis risk in APS (33, 34). However, 
studies in a mouse model of aPL-induced fetal loss have excluded 
a role for activating Fc receptors (30, 35). To determine whether 
Fc receptors are involved in aPL-mediated eNOS antagonism, we 
treated BAECs with NHIgG, intact polyclonal aPL, or bivalent 
F(ab)′2 fragments of polyclonal aPL (Supplemental Figure 2C). 
Whereas VEGF activation of eNOS occurred in NHIgG-treated 
cells, intact aPL and bivalent F(ab)′2 fragments of aPL antago-
nized eNOS activation to a comparable degree. Thus, the F(ab)′ 
Figure 3
eNOS antagonism by aPL and resulting changes in monocyte adhesion require β2GPI. (A) BAECs cultured in the presence or absence of serum 
for 18 hours were pretreated with NHIgG or aPL (100 μg/ml, 15 minutes), and eNOS activity stimulated by VEGF (100 ng/ml, 15 minutes) was 
measured. n = 4; *P < 0.05 versus no aPL. (B) BAECs were pretreated with control mouse IgG1 (10 μg/ml) or mouse monoclonal antibody to 
β2GPI (FC1, 10 μg/ml) for 15 minutes, and basal and VEGF-stimulated eNOS activity was measured. n = 4; *P < 0.05 versus basal, †P < 0.05 
versus control. (C) BAECs were pretreated with NHIgG or aPL, or antibodies to β2GPI (3F8 or 2aG4, 10 μg/ml) for 15 minutes, and basal and 
VEGF-stimulated eNOS activity was measured. n = 6, *P < 0.05 versus basal, †P < 0.05 versus NHIgG. (D) BAECs were treated with vehicle 
(control) or LPS (100 ng/ml) with or without control IgG (BBG, 10 μg/ml) or 3F8, in the presence or absence of the NO donor SNAP (NO, 20 
μmol/l) for 18 hours, and monocyte adhesion was evaluated. n = 4; *P < 0.05 versus control, †P < 0.05 versus no NO treatment. (E) BAECs 
were treated with vehicle or LPS with or without Ach (10 μmol/l), in the presence of NHIgG, aPL, BBG, 3F8, or 2aG4, and monocyte adhesion 
was evaluated. n = 4; *P < 0.05 versus no treatment, †P < 0.05 versus LPS alone. (F) BAECs were pretreated with 3F8, monomeric β2GPI 
(1.5 μg/ml), or β2GPI dimer (1.5 μg/ml) for 15 minutes, and basal and VEGF-stimulated eNOS activity was measured. n = 6; *P < 0.05 versus 
basal, †P < 0.05 versus VEGF alone.
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region of aPL is sufficient to antagonize eNOS and the Fc region is 
not required, indicating that Fc receptors are not required for the 
actions of aPL on eNOS.
eNOS antagonism and resulting increase in adhesion with aPL require 
apoER2. Since we found that aPL antagonism of eNOS is mediated 
by β2GPI and is mimicked by dimeric β2GPI, and since dimeric 
β2GPI has the capacity to bind directly to members of the LDLR 
family, including apoER2 and VLDLR (8, 14), we next studied the 
role of member(s) of the LDLR family using the inhibitor recep-
tor-associated protein (RAP) (ref. 36 and Figure 4A). In cells pre-
treated with GST control, polyclonal aPL blunted eNOS activa-
tion. In contrast, in cells pretreated with GST-RAP, aPL did not 
inhibit eNOS activity. These findings indicate that member(s) of 
the LDLR family expressed in endothelial cells are required for 
aPL-mediated eNOS antagonism. To determine whether apoER2 
is the transmembrane protein coupling aPL to eNOS, we assessed 
the effect of aPL on Ach-mediated increases in carotid vascular 
conductance in ApoER2+/+ versus ApoER2–/– mice. Whereas the 
administration of aPL blunted Ach-induced increases in vascu-
lar conductance in ApoER2+/+ mice (Figure 4B), aPL had no effect 
on the Ach response in ApoER2–/– mice (Figure 4C). To determine 
the requirement for apoER2 in direct aPL action on endothelial 
cells, we used siRNA to diminish expression of the receptor in 
BAECs and studied endothelial cell–monocyte adhesion (Figure 
4D). In apoER2 RNAi–treated cells, apoER2 protein expression 
was decreased by more than 90% (Figure 4D). Whereas apoER2 
knockdown had no effect on LPS-induced adhesion, 3F8-mediated 
adhesion was fully prevented.
Having found that aPL antagonism of eNOS and the resulting 
increase in endothelial cell–monocyte adhesion are mediated by both 
β2GPI and apoER2, we next examined the role of their interaction. 
In prior studies in isolated platelets, a soluble peptide based on the 
sequence of the first LDL-binding domain (BD1) of apoER2′, desig-
nated sBD1, prevented the interaction of domain V of β2GPI with the 
receptor (37, 38). We employed sBD1 in studies of eNOS antagonism 
by the anti-β2GPI antibody 3F8 in BAECs (Figure 4E), and found that 
Figure 4
eNOS antagonism by aPL and resulting changes in monocyte adhesion require apoER2 and β2GPI-apoER2 interaction. (A) BAECs were pre-
treated with GST (12 μg/ml) or GST-RAP (GST, 12 μg/ml; RAP 30 μg/ml) and either NHIgG or aPL (100 μg/ml for 15 minutes), and basal and 
VEGF-stimulated (100 ng/ml) eNOS activity was measured. n = 4; *P < 0.05 versus NHIgG. (B and C) ApoER2+/+ and ApoER2–/– mice were 
instrumented, and changes in carotid vascular conductance in response to eNOS activation were compared before and after treatment with 
aPL (2 mg i.v.). Dose-responses to Ach were determined sequentially at baseline (filled circles), 60 minutes after aPL treatment (open circles), 
and 10 minutes after L-NAME administration (inverted triangles). n = 6/group; *P < 0.05 versus baseline (ANOVA). (D) BAECs transfected with 
control (control RNAi) or double-stranded RNA targeting apoER2 were exposed to vehicle, LPS (100 ng/ml), control IgG (BBG, 10 μg/ml), or 
anti-β2GPI antibody (3F8, 10 μg/ml) for 18 hours, and monocyte adhesion was evaluated (upper panel). n = 4; *P < 0.05 versus no treatment, 
†P < 0.05 versus control RNAi. In parallel studies, whole cell lysates were immunoblotted for apoER2 and actin (lower panel). (E) BAECs were 
pretreated with 3F8 (2 μg/ml) in the presence of peptide with sequence identical to the second LDL-binding domain (sBD2, 125 μg/ml) or the 
first LDL-binding domain of apoER2 (sBD1, 125 μg/ml) for 15 minutes, and basal and VEGF-stimulated eNOS activity was measured. n = 6; 
*P < 0.05 versus basal, †P < 0.05 versus VEGF alone.
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whereas control peptide with the sequence of the second LDL-bind-
ing domain (sBD2) did not alter the antagonism of eNOS, sBD1 fully 
prevented the inhibition. Thus, apoER2 and interaction between BD1 
of the receptor and domain V of β2GPI are required for aPL antago-
nism of eNOS and the resulting increase in monocyte adhesion.
aPL blunts eNOS S1179 phosphorylation via PP2A. The basis for aPL 
antagonism of eNOS was next determined in studies in BAECs of 
the processes regulating the phosphorylation and dephosphoryla-
tion of the enzyme at S1179 (S1177 in human eNOS) and T497 
(11, 12, 39). In initial experiments evaluating the degree of eNOS 
phosphorylation, the cells were serum-starved for 24 hours to 
deplete β2GPI. Following serum starvation, neither VEGF-induced 
S1179 phosphorylation nor VEGF-induced T497 dephosphoryla-
tion was altered by polyclonal aPL (Supplemental Figure 3), paral-
Figure 5
aPL blunts eNOS S1179 phosphorylation and enzyme activation via PP2A. (A and B) BAECs were serum-starved for 18 hours, incubated with 
β2GPI (5 μg/ml for 1 hour), pretreated with NHIgG or aPL (100 μg/ml for 15 minutes), and incubated with VEGF (100 ng/ml for 0, 5, 10 minutes). 
Whole cell lysates were prepared and immunoblotted for phospho-eNOS and total eNOS using polyclonal phospho-S1179 eNOS antibody 
and monoclonal total eNOS antibody, respectively. (C and D) Samples were also immunoblotted using phospho-T497 eNOS and total eNOS 
antibody. In B and D, summary values shown are mean ± SEM. n = 6–8; *P < 0.05 versus time 0; †P < 0.05 versus NHIgG. (E and F) In paral-
lel studies samples were immunoblotted for phospho-S473 Akt and total Akt. The abundance of phospho-Akt/total Akt is expressed relative to 
abundance at 10 minutes to accommodate a lack of detection of phospho-Akt in some samples in the absence of VEGF stimulation (time 0). In 
F, summary values shown are mean ± SEM. n = 4; *P < 0.05 versus 10 minutes VEGF. (G) BAECs transfected with control (control RNAi) or 
double-stranded RNA targeting PP2A were serum-starved for 18 hours and incubated with β2GPI. The cells were further pretreated with NHIgG 
or aPL, and basal and VEGF-stimulated eNOS activity was measured. n = 6; *P < 0.05 versus basal, †P <0.05 versus NHIgG. Immunoblotting 
of whole cell lysates for PP2A and actin revealed approximately 50% knockdown of PP2A (inset).
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leling the lack of eNOS antagonism by aPL after serum starvation 
(Figure 3A). However, following reconstitution with recombinant 
human β2GPI (18, 19) (Supplemental Figure 1), aPL caused full 
inhibition of VEGF-induced S1179 phosphorylation (Figure 5, A 
and B); VEGF-induced T497 dephosphorylation was unaffected 
(Figure 5, C and D). To elucidate the basis for blunted eNOS s1179 
phosphorylation caused by aPL, potential changes in Akt activa-
tion were then interrogated in serum-starved cells following recon-
stitution with β2GPI. Whereas polyclonal aPL treatment blunted 
eNOS S1179 phosphorylation in response to VEGF (Figure 5, A 
and B), Akt phosphorylation at S473, indicative of activation of 
the kinase, was unaffected (Figure 5, E and F). Thus, aPL antago-
nize eNOS activity by attenuating the phosphorylation of S1179, 
and the actions of aPL occur distal to Akt.
In numerous paradigms, eNOS S1179 is dephosphorylated 
and eNOS enzymatic activity is consequently decreased by the 
phosphatase PP2A (39, 40). We therefore assessed the role of PP2A 
in aPL-induced changes in eNOS activity by siRNA knockdown. 
PP2A knockdown of approximately 50% (Figure 5G, inset) pre-
vented aPL antagonism of eNOS activation by VEGF (Figure 5G). 
Thus, aPL antagonize eNOS by attenuating S1179 phosphoryla-
tion via the activation of the phosphatase PP2A.
aPL-induced leukocyte–endothelial cell adhesion in vivo is mediated by 
eNOS and apoER2. Having demonstrated in cultured endothelial 
cells that aPL antagonize eNOS activity resulting in increased 
monocyte–endothelial cell adhesion, we determined whether 
these mechanisms are operative in vivo in studies of leukocyte–
endothelial cell adhesion in the mouse mesenteric microcircula-
tion. Under the control conditions present with NHIgG treat-
ment, leukocyte adhesion (still images are shown in Figure 6, A 
and B) and wbc velocity (Figure 6C) were similar in eNOS+/+ and 
eNOS–/– mice. Despite the difference in endothelium-derived NO 
in these mice, similar leukocyte–endothelial cell adhesion has been 
observed in prior studies at baseline, and this has been attributed 
to compensatory mechanisms (41). As expected, aPL administra-
tion to eNOS+/+ mice caused an increase in leukocyte–endothelial 
cell interaction (Figure 6A), and an associated decrease in leuko-
cyte velocity (Figure 6C). In contrast, in eNOS–/– mouse aPL had 
minimal effect on leukocyte interaction with endothelium (Fig-
ure 6B) and therefore did not alter leukocyte velocity (Figure 6C). 
Videos of the intravital fluorescence microscopy are provided in 
Supplemental Videos 1–4. These results indicate that eNOS is 
critical to aPL-induced increases in leukocyte adhesion to vascu-
lar endothelium in vivo.
Figure 6
aPL-induced leukocyte–endothelial cell adhesion in mice is mediated by eNOS and apoER2. eNOS+/+ (A) and eNOS–/– (B) mice were i.p. 
injected with NHIgG or aPL (100 μg) and 24 hours later prepared for intravital microscopy. Leukocytes were fluorescence-labeled by injection 
of rhodamine 6G, and the mesentery was exposed for the observation and recording of images of leukocyte adhesion and rolling. Represen-
tative still images are shown (leukocytes indicated by arrows). (C) Velocity of leukocyte (wbc) rolling in eNOS+/+ and eNOS–/– mice. Parallel 
experiments were performed in ApoER2+/+ (D) and ApoER2–/– (E) mice, and representative still images are shown. (F) Velocity of leukocyte 
(wbc) rolling in ApoER2+/+ and ApoER2–/– mice. In C and F, values are mean ± SEM. n = 5–7/group; *P < 0.05 vs NHIgG, †P < 0.05 versus 
eNOS+/+ or ApoER2+/+.
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Having demonstrated in cell culture that both aPL-induced 
eNOS antagonism and the resulting increase in adhesion require 
apoER2, we investigated the role of apoER2 in vivo. In ApoER2+/+ 
mice, aPL caused an increase in leukocyte–endothelial cell interac-
tion (Figure 6D), resulting in decreased leukocyte velocity (Figure 
6F). In contrast, in ApoER2–/– mice aPL had no effect on leuko-
cyte interaction with endothelium (Figure 6E) and therefore did 
not change leukocyte velocity (Figure 6F). Videos of the intravital 
fluorescence microscopy are provided in Supplement Videos 5–7. 
Thus, aPL-induced increases in leukocyte–endothelial cell adhe-
sion in vivo require apoER2.
aPL-induced thrombosis is mediated by eNOS and apoER2. Prior stud-
ies have demonstrated that aPL-induced changes in endothelial 
cell adhesion play a major role in the thrombosis invoked by the 
antibodies (16). In addition, it is well established that NO derived 
from eNOS attenuates both leukocyte–endothelial cell interac-
tions and thrombosis (42–46). We therefore determined whether 
eNOS antagonism underlies aPL-induced thrombus formation 
in studies of eNOS+/+ and eNOS–/– mice (Figure 7, A–C). As previ-
ously observed (42, 47), under the control conditions present with 
NHIgG treatment, the time to vessel occlusion was reduced in 
eNOS–/– versus eNOS+/+ mice (Figure 7C). With aPL treatment of 
eNOS+/+ mice, the time to vessel occlusion compared with NHIgG 
was shortened, indicating enhanced thrombus formation (Figure 
7A, which displays still images at 300 seconds, and Figure 7C). In 
contrast, aPL did not alter thrombosis or change the time to occlu-
sion in eNOS–/– mice (Figure 7, B and C).
The role of apoER2 in aPL-induced thrombosis was then investi-
gated. In ApoER2+/+ mice, aPL enhanced thrombus formation (Fig-
ure 7D), resulting in a decrease in the time to total vessel occlusion 
(Figure 7F). In contrast, in ApoER2–/– mice aPL had no effect on 
thrombus formation (Figure 7E) and therefore did not change the 
time to occlusion (Figure 7F). Thus, in addition to mediating aPL-
induced increases in endothelial cell–leukocyte adhesion, apoER2 
and eNOS are also critically involved in aPL-induced thrombosis.
Discussion
In the present study we have demonstrated that aPL inhibit the acti-
vation of eNOS and that the resulting decline in NO production 
underlies the promotion of leukocyte–endothelial cell adhesion 
Figure 7
aPL-induced thrombosis in mice is mediated by eNOS and apoER2. eNOS+/+ (A) and eNOS–/– (B) mice were i.p. injected with NHIgG or 
aPL (100 μg) and 24 hours later prepared for intravital microscopy. Platelets were fluorescence-labeled by injection of anti–mouse GPIbβ 
antibody, and the mesentery was exposed for the observation and recording of images of thrombi. Representative still images at 300 sec-
onds are shown. (C) Time required for complete vessel occlusion in eNOS+/+ and eNOS–/– mice. Parallel experiments were performed in 
ApoER2+/+ (D) and ApoER2–/– (E) mice, and representative still images at 300 seconds are shown. (F) Time required for complete vessel 
occlusion in ApoER2+/+ and ApoER2–/– mice. In C and F, values are mean ± SEM. n = 5–7/group; *P < 0.05 versus NHIgG, †P < 0.05 versus 
eNOS+/+, ‡P < 0.05 versus ApoER2+/+.
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and thrombus formation by aPL (summary in Figure 8). Consider-
ing the primary role of eNOS-derived NO in both the anti-adhesive 
and antithrombotic characteristics of healthy endothelium (10), 
eNOS antagonism by aPL is likely to be a critical initiating process 
in the pathogenesis of the vascular manifestations of APS.
We found that aPL antagonize eNOS activity in cultured 
endothelial cells derived from multiple species, including humans. 
Studies of carotid vascular conductance in mice also showed that 
aPL attenuate eNOS activation, demonstrating the physiologic 
importance of this effect in vivo. These observations are consis-
tent with the finding in APS patients that endothelium-depen-
dent, NO-dependent flow-mediated dilation of the brachial artery 
is impaired, whereas endothelium-independent vasodilation is 
normal (48, 49). In addition, in APS patients there is a negative 
correlation between flow-mediated dilation and circulating levels 
of the adhesion molecules VCAM-1 and ICAM-1 (48). Consistent 
with this inverse relationship between the capacity for NO produc-
tion and the degree of vascular inflammation in APS patients, our 
work in both cultured endothelial cells and in vivo in mice now 
reveals a causal link between aPL-induced eNOS antagonism and 
increased leukocyte–endothelial cell adhesion.
To define the underlying mechanisms, we examined the role of 
β2GPI. Using both loss-of-function and gain-of-function strate-
gies, we determined that β2GPI mediates eNOS antagonism by 
aPL. Furthermore, monoclonal Ab to domain I of β2GPI, which is 
the domain primarily targeted by pathogenic aPL that recognize 
β2GPI (7, 21, 22, 24, 26, 27, 50), and not Ab to domain II, caused 
eNOS antagonism and the resulting increase in adhesion (Figure 
8, i). Moreover, purified dimeric β2GPI, but not monomeric β2GPI, 
inhibited eNOS activation. Thus, we have demonstrated that the 
recognition of domain I of β2GPI and its dimerization are the 
upstream events in aPL antagonism of eNOS and its consequences. 
We further discovered that the downstream process leading to eNOS 
inhibition is attenuated eNOS S1179 phosphorylation caused by 
the activation of the phosphatase PP2A (Figure 8, iii).
There is considerable evidence that complement activation plays 
a role in the ultimate manifestations of APS. The inhibition of the 
complement cascade by the C3 convertase inhibitor complement 
receptor 1–related gene protein y–Ig (Crry-Ig) or the administration 
of anti-C5 monoclonal antibody reverses aPL-mediated thrombosis 
in mice, and C3- and C5-null mice are resistant to the effects of 
aPL (51). Complement activation also participates in aPL-induced 
fetal loss during pregnancy (28). Our finding that aPL-mediated 
eNOS inhibition does not require complement is consistent with 
the recent proposal that APS pathogenesis entails initial direct 
effects of aPL on endothelium, and possibly also on platelets, 
which are then amplified by the ensuing activation of complement 
via mediators such as C3a and C5a (51). Our elucidation of the 
proximal mechanisms responsible for aPL effects on endothelium 
now makes it possible to test potential cause-effect linkage between 
endothelial aPL action and complement activation.
To date, the basis by which pathogenic aPL recognition of 
β2GPI on the cell surface elicits a transmembrane signal to mod-
ify intracellular events in endothelium has been poorly under-
stood (52–54). In biochemical analyses, it has been demonstrated 
that β2GPI binds directly to LDLR family members including 
apoER2, VLDLR, LRP, and megalin (14), and apoER2 and VLDLR 
are expressed in endothelium (55, 56). Using RAP in cultured 
endothelial cells, we first showed that an LDLR family protein is 
required for aPL-mediated eNOS inhibition. Then in in vivo stud-
ies, we identified that receptor to be apoER2. We provided further 
evidence of the requirement for apoER2 in studies of aPL-induced 
endothelial cell–monocyte adhesion entailing knockdown of the 
receptor in endothelium by RNAi. Moreover, by using a recombi-
nant soluble form of LDL-binding domain 1 of ApoER2 (sBD1) 
that inhibits dimeric β2GPI binding via domain V to apoER2 (38, 
57), we showed that interaction between β2GPI and the recep-
tor mediates aPL actions in endothelium (Figure 8, ii). We then 
expanded on these numerous in vitro and ex vivo findings in stud-
ies of leukocyte–endothelial cell adhesion and thrombus formation 
in wild-type, eNOS–/–, and ApoER2–/– mice. Although the results for 
aPL-induced thrombosis in eNOS+/+ versus eNOS–/– mice should be 
interpreted conservatively because of the differences in thrombo-
sis under control conditions, the cumulative findings indicate that 
apoER2 and eNOS are important linchpins in aPL vascular actions 
in vivo. Thus, the basis for transmembrane signaling induced by 
aPL binding to extracellular β2GPI in endothelium has now been 
identified, and the molecular events by which apoER2 initiates 
intracellular processes in endothelium including PP2A activation 
can now be investigated.
Although direct actions of aPL on platelets are likely contribu-
tory to APS-related thrombosis, there is a major role for the acti-
vation of endothelial cell adhesion in aPL-induced thrombus 
formation (9, 58, 59). This has been most clearly indicated by 
studies demonstrating that ICAM1–/– mice and mice administered 
anti–VCAM-1 monoclonal antibody are fully protected from aPL-
induced thrombus formation (16). However, the presence of aPL 
and aPL actions on endothelium are not sufficient, because most 
of the time patients with circulating aPL do not have thrombo-
ses. A “two-hit hypothesis” has been proposed in which aPL (the 
first hit) induces a threshold cellular perturbation in endothelium, 
or possibly in platelets, and another condition (the second hit) is 
required to trigger actual clot formation (60). In most prior stud-
Figure 8
aPL promote leukocyte adhesion and thrombosis by antagonizing 
eNOS via β2GPI, apoER2, and the phosphatase PP2A. (i) aPL bind-
ing to domain I of β2GPI causes β2GPI dimerization and (ii) interac-
tion between domain V of β2GPI and the first LDL-binding domain of 
apoER2 (BD1). Through yet-to-be-determined mechanism(s), the inter-
action of β2GPI with apoER2 causes (iii) increased activation of PP2A. 
This promotes the dephosphorylation of S1179 of eNOS, yielding 
decreased enzymatic activity and a decline in bioavailable NO, which 
results in increased leukocyte adhesion and increased thrombosis.
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ies of APS-related thrombosis in rodents, as well as in our experi-
ments, thrombus formation must be induced (16). The second hit 
may involve a proinflammatory stimulus, since rats administered 
aPL with anti-β2GPI activity have spontaneous thromboses if they 
also receive LPS (61). These observations have led to the suggestion 
that infectious agents may play a dual role in APS pathogenesis 
by initially triggering the generation of cross-reactive anti-β2GPI 
antibodies (first hit) due to considerable amino acid sequence 
homology between β2GPI and a number of bacterial and viral 
components, and then by inducing an inflammatory response that 
serves as the second hit (62). With the molecular underpinning of 
the first hit now in hand, the nature of possible second-hit condi-
tions can be better interrogated.
The proximal processes by which aPL cause changes in 
endothelial cell behavior have been elusive (52–54, 63). We now 
provide multiple lines of evidence demonstrating that aPL-induced 
increases in leukocyte–endothelial cell adhesion and thrombus for-
mation are caused by eNOS antagonism, which is due to impaired 
S1179 phosphorylation mediated by β2GPI, apoER2, and PP2A. 
The identification of these molecules and the elucidation of how 
they interplay to invoke the endothelial actions of aPL and their 
sequelae now provide the framework for the development of new 
strategies to combat APS. With the new knowledge gained, it is 
now possible that the lifelong requirement for anticoagulation in 
the APS patient will be replaced by a mechanism-based therapy 
offering both far fewer complications and greater efficacy against 
this often devastating condition.
Methods
Animal models. In vivo studies were performed in male C57BL/6 mice, 
ApoER2+/+ and ApoER2–/– littermates (129SvEv × C57BL/6J), and eNOS+/+ 
and eNOS–/– littermates (C57BL/6). All animal experiments were approved 
by the Institutional Animal Care and Utilization Committees at the Uni-
versity of Texas Southwestern Medical Center, the Johns Hopkins Universi-
ty School of Medicine, and the University of Rochester School of Medicine 
and Dentistry. (Some experiments were performed at the Johns Hopkins 
University School of Medicine under C.N. Morrell.)
Cell culture and transfection. Primary BAECs were isolated and stud-
ied using previously described methods (64, 65), and HAECs (Cambrex 
Corp.) were cultured in EGM2 media (Cambrex Corp.) and used within 
3–7 passages. MFLM-91U mouse endothelial cells were provided by Ann 
Akeson (Children’s Medical Center, Cincinnati, Ohio, USA) and cultured 
in Ultraculture Media (Cambrex Corp.) (66, 67). U937 monocytes (human 
histiocytic lymphoma, ATCC) were grown in RPMI 1640 Medium (Sigma-
Aldrich) containing 10% FBS. In siRNA experiments, BAECs were trans-
fected with siRNAs using LipofectAMINE 2000 (Invitrogen) and studied 
48 hours later. Double-stranded RNA with sequence 5′-CCAAGCUG-
CAAUCAUGGAA-3′ or 5′-ACUGGAAGCGGAAGAAUAC-3′ was designed 
to target the open reading frame of the bovine PP2A catalytic subunit 
Cα (accession number M16968) (68) or bovine apoER2 (accession num-
ber XM_865091), respectively, and control dsRNA was purchased from 
Dharmacon (catalog D-001210-01-20).
Antibody preparation. NHIgG was obtained from healthy non-autoim-
mune individuals. Polyclonal aPL were isolated from patients with APS, 
which were characterized as having high-titer aPL Ab (>140 GPL U), 
thromboses, and/or pregnancy losses (32). The relevant clinical and labo-
ratory features of the patients who provided aPL are given in Supplemen-
tal Table 1. Individuals provided informed consent before participating 
in these studies. All protocols were approved by the Institutional Review 
Board of Hospital for Special Surgery. The IgGs were purified by affinity 
chromatography using protein G–Sepharose chromatography columns 
(Amersham Biosciences) (31, 32). Endotoxin was removed using Cen-
triprep ultracentrifugation devices (Millipore), and lack of endotoxin was 
confirmed using the Limulus amebocyte lysate assay (30). Bivalent F(ab′)2 
fragments of polyclonal aPL were prepared by digestion of purified aPL 
IgG pooled from patients using immobilized pepsin (Pierce Chemical Co.). 
The digested supernatants were passed through protein G–Sepharose to 
remove remaining intact IgG. Their purity was assessed by Western blot 
analysis using an antibody specific for the F(ab′)2 fragments, and their aPL 
reactivity was demonstrated by ELISA (30). Mouse monoclonal aPL FC1 
(IgG1) obtained from NZW × BXSB F1 mice that recognizes β2GPI was 
provided by Marc Monestier (Temple University, Philadelphia, Pennsylva-
nia, USA) (20, 27). FC1 was purified from hybridoma supernatant by affin-
ity chromatography on recombinant protein G–agarose. Matching mouse 
monoclonal IgG1 isotype control mAb was obtained from Sigma-Aldrich. 
Mouse monoclonal antibodies directed to either domain I or domain II of 
β2GPI (3F8 and 2aG4, respectively) and the control mouse monoclonal 
antibody BBG3 were prepared as previously described (69, 70).
Monocyte adhesion assay. The adhesion of U937 monocytes to monolayers 
of BAECs was evaluated as described previously (17). Confluent BAECs 
were exposed to aPL (100 μg/ml), NHIgG (100 μg/ml), anti-β2GPI mouse 
monoclonal antibody (3F8 or 2aG4, 10 μg/ml), control mouse monoclo-
nal antibody BBG3 or subtype-matched control mouse IgG (10 μg/ml), 
or LPS (Sigma-Aldrich, 100 ng/ml) for 18 hours. In selected experiments, 
BAECs were exposed to LPS in the absence or presence of the eNOS ago-
nist Ach (10 μmol/l) and either NHIgG or aPL (100 μg/ml). In additional 
studies, cells were also treated with the NO donor SNAP (20 μmol/l). Sub-
sequently, BAECs were washed with PBS, U937 monocytes (1 × 106cells/
dish) were added and incubated with BAEC under rotating conditions 
(benchtop incubator at 63 rpm) at 21°C for 15 minutes, nonadhering 
cells were removed by gentle washing with PBS, cells were fixed with 1% 
paraformaldehyde, and the number of adherent cells was determined in 
triplicate per ×40 magnification field.
eNOS activation assay. eNOS activation was assessed in intact endothelial 
cells by measuring the conversion of [14C]l-arginine to [14C]l-citrulline 
(64). Cells were preincubated with NHIgG or aPL (100 μg/ml), and eNOS 
activity was then determined over 15 minutes in the continued presence of 
NHIgG or aPL, in the absence (basal) or presence of VEGF (2.4 pmol/l, 100 
ng/ml) or Ach (10 μmol/l). In selected experiments, the cells were treated 
with anti-β2GPI monoclonal antibody (FC1, 3F8, or 2aG4; 10 μg/ml). 
Additional experiments were performed in cells pretreated with recombi-
nant monomeric β2GPI (apple 2-β2GPI, 1.5 μg/ml) or dimerized β2GPI 
(apple 4-β2GPI, 1.5 μg/ml), which were was constructed and expressed as 
described previously (15, 38). Studies were also done to assess the role of 
LDLR family members in cells pretreated with GST-RAP or GST control 
(12 μg/ml for 15 minutes), which were purified as previously reported, and 
purity was confirmed by SDS-PAGE (36). The role of β2GPI-apoER2 inter-
action was determined using recombinant soluble LDL-binding domain 1 
of apoER2 (sBD1, 125 μg/ml) or the control peptide representing LDL-
binding domain 2 (sBD2) (37). Separate sets of experiments were done in 
BAECs treated with RNAi targeted to knockdown apoER2 or PP2A. Find-
ings were replicated in 3 or more independent experiments.
Carotid vascular conductance. To determine whether aPL alters eNOS activ-
ity in vivo, we measured Ach-mediated increases in carotid vascular conduc-
tance before and after NHIgG or aPL administration to 12- to 18-week-old 
male mice (17). Mice were anesthetized with tiletamine (4 mg/kg), zolazepam 
(4 mg/kg), and xylazine (20 mg/kg) given i.p., catheters were placed in the 
right jugular vein and common carotid artery, and the mice were switched 
to inhalation anesthesia (1% isoflurane). A Doppler ultrasound flow probe 
(Crystal Biotech) was placed around the left common carotid artery, and 
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arterial pressure, carotid blood flow velocity, and calculated carotid vascular 
conductance (mean blood flow velocity/mean arterial pressure) were moni-
tored and recorded (MacLab, AD Instruments). Vasodilator responses to i.v. 
injections of Ach (4–64 ng in a volume of 1–16 μl) were evaluated sequen-
tially at baseline, 60 minutes after administration of NHIgG or aPL (2 mg 
i.v.), and 10 minutes after treatment with L-NAME (10 mg/kg i.v.).
Immunoblot analyses. Immunoblot analyses were performed to assess 
eNOS and Akt phosphorylation using polyclonal anti–phospho-S1179 
eNOS antibody, polyclonal anti–phospho-T497 eNOS antibody, and 
polyclonal anti–phospho-S473 Akt antibody (Cell Signaling Technology). 
Total eNOS and Akt abundance was assessed using eNOS monoclonal 
antibody (BD Biosciences — Pharmingen) and Akt polyclonal antibody 
(Cell Signaling Technology). BAECs were placed in serum-free, phenol red–
free DMEM overnight, human β2GPI (5 μg/ml; Haematologic Technolo-
gies Inc.) was added for 1 hour, and cells were preincubated with NHIgG or 
aPL (100 μg/ml) and treated with VEGF (2.4 pmol/l, 100 ng/ml) for 0–10 
minutes. Findings were confirmed in 3 independent experiments. The loss 
of media-derived bovine β2GPI with serum starvation and the reconstitu-
tion with human β2GPI were confirmed by immunoblotting with mono-
clonal antibody to β2GPI (2aG4) (69, 70). Selected sets of immunoblot 
analyses were performed to assess the expression of apoER2 or PP2A after 
RNAi knockdown using anti-apoER2 rabbit polyclonal antibody (71) or 
anti-PP2A mouse monoclonal antibody (Millipore).
Leukocyte adhesion and thrombus formation in vivo. Leukocyte adhesion was 
determined as described previously (72). Briefly, male mice (5–8 weeks old) 
were i.p. injected with NHIgG or aPL (100 μg) and 24 hours later prepared 
for intravital microscopy. All leukocytes were fluorescence-labeled by injec-
tion of rhodamine 6G (100 μl of 0.05% solution i.v.), and the mesentery was 
exposed for the observation and recording of images of leukocyte adhesion 
and rolling using a Retiga digital camera (×200 magnification; QImaging). 
The velocity of leukocyte rolling was calculated by measuring the distance 
leukocytes traveled between frames. It should be noted that velocity was 
found to be similar in control (NHIgG-treated) eNOS+/+ versus eNOS–/– 
mice, as has been observed for baseline adhesion to eNOS+/+ versus eNOS–/– 
endothelium in some but not all prior reports (41, 73, 74). Thrombus for-
mation was assessed as described previously (47, 75). Briefly, 24 hours fol-
lowing i.p. injection with NHIgG or aPL (100 μg/mouse), mice were i.v. 
injected with fluorescence-labeled anti–mouse GPIbβ antibody, which tar-
gets the platelet GPIb-V-IX complex. Then the mesenteric microcirculation 
was exteriorized, and thrombosis was induced by ferric chloride (10%, on 
Whatman filter paper for 45 seconds). Thrombus formation in arterioles 
was documented by capturing images (×200 magnification) every 1 second 
until total vessel occlusion occurred.
Statistics. All data are expressed as mean ± SEM. Two-tailed Student’s 
t test or ANOVA was used to assess differences between 2 groups or among 
more than 2 groups, respectively, with Newman-Keuls post-hoc testing fol-
lowing ANOVA. P values less than 0.05 were considered significant.
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